Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064726 · ClinicalTrials.gov registry record · Phase 1
A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01064726 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT01064726, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
After a nasal allergen challenge it should be possible to measure markers of inflammation that may be useful to assess the properties of future drugs. If these markers are reproducible and impacted by the study drugs they could be useful for future drug development.
Interventions
- DRUG Placebo
- DRUG Ibuprofen
- DRUG Fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01064726
The ClinicalTrials.gov registry entry for NCT01064726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01064726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01064726 about?
NCT01064726 is a clinical study titled "A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.". After a nasal allergen challenge it should be possible to measure markers of inflammation that may be useful to assess the properties of future drugs. If these markers are reproducible and impacted by the study drugs they could be useful for future drug development.
What is the current status of trial NCT01064726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01064726?
The interventions under investigation include: Placebo (DRUG), Ibuprofen (DRUG), Fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT01064726?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.